Replies to post #54418 on Biotech Values

[DewDiligence]

>Any thoughts on how intense the competition might be from Schering's boceprevir?<

There’s been a lot already written on this—here and elsewhere. If you read the posts in question, I think you’ll be able to make an assessment. Regards, Dew